Trials / Withdrawn
WithdrawnNCT03390647
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Adult Male Participants
A Phase 1 Clinical Study of E6130 - Clinical Pharmacology Study in Healthy Adult Male Subjects
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- EA Pharma Co., Ltd. · Industry
- Sex
- Male
- Age
- 20 Years – 44 Years
- Healthy volunteers
- Accepted
Summary
The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple oral doses of E6130 in Japanese healthy adult male participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E6130 | Oral dose |
| DRUG | Placebo | E6130-matched placebo |
Timeline
- Start date
- 2017-12-21
- Primary completion
- 2019-03-01
- Completion
- 2019-03-01
- First posted
- 2018-01-04
- Last updated
- 2018-07-31
Source: ClinicalTrials.gov record NCT03390647. Inclusion in this directory is not an endorsement.